Browse > Article
http://dx.doi.org/10.17480/psk.2016.60.1.21

Effect of Baicalin on the Ex vivo Production of Cytokines in Pristane-Induced Lupus Mice  

Chae, Byeong Suk (College of Pharmacy, Woosuk University)
Publication Information
YAKHAK HOEJI / v.60, no.1, 2016 , pp. 21-28 More about this Journal
Abstract
Systemic lupus erythematosus (SLE) is characterized by dysregulatory production of proinflammatory cytokines and helper T (Th) cytokine-dependent autoantibody production. This study aims to investigate the protective effect of baicalin on the dysregulatory production of proinflammatory cytokines and Th cytokines in pristane-induced lupus mice. Mice were received i.p. a single injection of 0.5 ml of pristane, and then, later about 3 months, were used as a pristane-induced lupus model. The pristane-induced lupus mice were administrated orally with baicalin 50 mg/kg once in a day for 10 days. Immune cells obtained from the pristane-primed lupus control group (lupus control) and baicalin-treated pristaneprimed lupus mouse group (BAC lupus) were cultured for 24 h or 36 h with/without mitogens. These results demonstrated that LPS-induced production of macrophage and splenic TNF-${\alpha}$ and Con A-induced production of thymic IFN-${\gamma}$ were attenuated in BAC lupus compared to lupus control, while LPS-stimulated production of macrophage IL-10, Con A-stimulated production of splenic IL-10 and, $PGE_2$-reduced production of splenic IFN-${\gamma}$ enhanced. Therefore, these findings suggest that baicalin may protect from autoimmunity and disease activity in lupus via modulatory effect of proinflammatory cytokine overproduction and Th cytokine imbalance.
Keywords
baicalin; lupus; TNF-${\alpha}$; IL-6; IL-10; IFN-${\gamma}$;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Nagy, G., Koncz, A. and Perl, A. : T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25, 123 (2005).   DOI
2 Chae, B. S. and Shin, T. Y. : Immunoregulatory abnormalities of T cells and hyperreactivity of B cells in the in vitro immune response in pristane-induced lupus mice. Arch. Pharm. Res. 30, 191 (2007).   DOI
3 Xu, L., Zhang, L., Yi, Y., Kang, H. K. and Datta, S. K. : Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10, 411 (2004).   DOI
4 Takeno, M., Nagafuchi, H., Kaneko, S., Wakisaka, S., Oneda, K., Takeba, Y., Yamashita, N., Suzuki, N., Kaneoka, H. and Sakane, T. : Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J. Immunol. 158, 3529 (1997).
5 Reininger, L., Santiago, M. L., Takahashi, S., Fossati, L. and Izui, S. : T helper cell subsets in the pathogenesis of systemic lupus erythematosus. Ann. Med. Interne. (Paris) 147, 467 (1996).
6 Ishikawa, S., Akakura, S., Abe, M., Terashima, K., Chijiiwa, K., Nishimura, H., Hirose, S. and Shirai, T. : A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. J. Immunol. 161, 1267 (1998).
7 Portales-Perez, D., Gonzalez-Amaro, R., Abud-Mendoza, C. and Sanchez-Armass, S. : Abnormalities in CD69 expression, cytosolic pH and $Ca^{2+}$ during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 6, 48 (1997).   DOI
8 Crispin, J. C., Martinez, A., de Pablo, P., Velasquillo, C. and Alcocer-Varela, J. : Participation of the CD69 antigen in the Tcell activation process of patients with systemic lupus erythematosus. Scand. J. Immunol. 48, 196 (1998).   DOI
9 Takeuchi, T., Tsuzaka, K., Abe, T., Yoshimoto, K., Shiraishi, K., Kameda, H. and Amano, K. : T cell abnormalities in systemic lupus erythematosus. Autoimmunity 38, 339 (2005).   DOI
10 Jordan, N. and D'Cruz, D. : Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther. Adv. Musculoskelet Dis. 7, 234 (2015).   DOI
11 Steiman, A. J., Gladman, D. D., Ibanez, D., Noamani, B., Landolt-Marticorena, C., Urowitz, M. B. and Wither, J. E. : Lack of Interferon and proinflammatory cyto/chemokines in serologically active clinically quiescent systemic lupus erythematosus. J. Rheumatol. 42, 2318 (2015).   DOI
12 Aringer, M. and Smolen, J. S. : SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res. Ther. 5, 172 (2003).
13 Liang, B., Gardner, D. B., Griswold, D. E., Bugelski, P. J. and Song, X. Y. : Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119, 296 (2006).   DOI
14 Chun, H. Y., Chung, J. W., Kim, H. A., Yun, J. M., Jeon, J. Y., Ye, Y. M., Kim, S. H., Park, H. S. and Suh, C. H. : Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27, 461 (2007).   DOI
15 Dean, G. S., Tirrell-Price, J., Crawley, E. and Isenberg, D. A. : Cytokines and systemic lupus erythematosus. Ann. Rheum. Dis. 59, 243 (2000).   DOI
16 Haas, C., Ryffel, B. and Le Hir, M. : IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J. Immunol. 160, 3713 (1998).
17 Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V. and Reeves, W. H. : Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188, 985 (1998).   DOI
18 Li-Weber, M. : New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat. Rev. 35, 57 (2009).   DOI
19 Tsai, C. Y., Wu, T. H., Tsai, S. T., Chen, K. H., Thajeb, P., Lin, W. M., Yu, H. S. and Yu, C.L. : Cerebrospinal fluid interleukin- 6, prostaglandin $E_2$ and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand. J. Rheumatol. 23, 57 (1994).   DOI
20 Chae, B. S., Shin, T. Y., Kim, D. K., Eun, J. S., Leem, J. Y. and Yang, J. H. : Prostaglandin $E_2$-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice. Arch. Pharm. Res. 31, 503 (2008).   DOI
21 Gao, Z., Huang, K., Yang, X. and Xu, H. : Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim. Biophys. Acta. 1472, 643 (1999).   DOI
22 Wang, H. and Liu, D. : Baicalin inhibits high-mobility group box 1 release and improves survival in experimental sepsis. Shock 41, 324 (2014).   DOI
23 Zhu, J., Wang, J., Sheng, Y., Zou, Y., Bo, L., Wang, F., Lou, J., Fan, X., Bao, R., Wu, Y., Chen, F., Deng, X. and Li, J. : Baicalin improves survival in a murine model of polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis. PLoS One 7, e35523 (2012).   DOI
24 Liu, L. L., Gong, L. K., Wang, H., Xiao, Y., Wu, X. F., Zhang, Y. H., Xue, X., Qi, X. M. and Ren, J. : Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock. Biochem. Pharmacol. 75, 914 (2008).   DOI
25 Beebe, A. M., Cuab, D. J. and de Waal Malefyt, R. : The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine & Growth Factor Reviews 13, 403 (2002).   DOI
26 Svenungsson, E., Fei, G. Z., Jensen-Urstad, K., de Faire, U., Hamsten, A. and Frostegard, J. : TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12, 454 (2003).   DOI
27 Xu, J., Huang, R., Yang, Y. J., Jin, S. J. and Zhang, J. F. : Effects of baicalin on apoptosis in rats with autoimmune encephalomyelitis. Zhongguo Dang Dai Er Ke Za Zhi 13, 665 (2011).
28 Yang, J., Yang, X. and Li, M. : Baicalin, a natural compound, promotes regulatory T cell differentiation. BMC Complement Altern. Med. 12, 64 (2012).
29 Shacter, E., Arzadon, G. K. and Williams, J. : Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 80, 194 (1992).
30 Chae, B. S. : Baicalin amelirates dysimmunoregulation in pristane-induced lupus mice: production of IL-6 and PGE2 and activation of T cells. Nat. Prod. Sci. 17, 354 (2011).
31 Qu, H., Bian, W. and Xu, Y. : A novel NF-${\kappa}B$ inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice. Exp. Ther. Med. 8, 100 (2014).   DOI
32 Miyagaki, T., Fujimoto, M. and Sato, S. : Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. Int. Immunol. 27, 495 (2015).   DOI
33 Sim, J. H., Kim, H. R., Chang, S. H., Kim, I. J., Lipsky, P. E. and Lee, J. : Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus. Arthritis Res. Ther. 17, 190 (2015).   DOI
34 Kalinski, P. : Regulation of immune responses by prostaglandin $E_2$. J. Immunol. 188, 21 (2012).   DOI
35 Piliero, P. and Furie, R. : Functional asplenia in systemic lupus erythematosus. Semin. Arthritis Rheum. 20, 185 (1990).   DOI
36 Hinson., R. M., Williams, J. A. and Shacter, E. : Elevated interleukin 6 is induced by prostaglandin $E_2$ in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. U S A 93, 4885 (1996).   DOI
37 Mene, P., Pecci, G., Cinotti, G. A., Pugliese, G., Pricci, F. and Pugliese, F. : Eicosanoid synthesis in peripheral blood monocytes: a of disease activity in lupus nephritis. Am. J. Kidney Dis. 32, 778 (1998).   DOI
38 Dillon, A. M., Stein, H. B. and English, R. A. : Splenic atrophy in systemic lupus erythematosus. Ann. Intern. Med. 96, 40 (1982).   DOI
39 Yang, X., Sun, B., Wang, H., Yin, C., Wang, X. and Ji, X. : Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling. J. Biomed. Res. 29, 232 (2015).
40 Panarese, A., D'Andrea, V., Pironi, D. and Filippini, A. : Thymectomy and systemic lupus erythematosus (SLE). Ann. Ital. Chir. 85, 617 (2014).
41 Gottschalk, T. A., Tsantikos, E. and Hibbs, M. L. : Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front. Immunol. 6, 550 (2015).
42 Mathian, A., Hie, M., Cohen-Aubart, F. and Amoura, Z. : Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75, 835 (2015).   DOI
43 Balomenos, D., Rumold, R. and Theofilopoulos, A. N. : Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101, 364 (1998).   DOI
44 Harigai, M., Kawamoto, M., Hara, M., Kubota, T., Kamatani, N. and Miyasaka, N. : Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J. Immunol. 181, 2211 (2008).   DOI